Pancancer analysis of DCTPP1 and the impact of the combined knockdown of DCTPP1 with docetaxel on breast cancer

Introduction : Examine the carcinogenic function of DCTPP1 in breast cancer. Methods : A pancancer study revealed that high DCTPP1 expression was associated with poor prognosis. In MCF-7 cells, DCTPP1 knockdown (si-DCTPP1) was assessed via MTT, qRT‒PCR, Western blot, adhesion, scratch, and Transwell assays. In vivo tumorigenesis was used to measure tumor growth in vivo. DCTPP1 and EMT markers were detected via immunohistochemistry. Results : DCTPP1 was elevated in all tumor types and was linked to negative outcomes. In breast cancer, high DCTPP1 expression was associated with poor prognosis and possible immune evasion, as determined via bioinformatics analysis. si-DCTPP1 suppressed invasion, migration, and proliferation by increasing E-cadherin, decreasing TGF-β, and inhibiting cell adhesion. The combination of si-DCTPP1 and docetaxel synergistically intensified these effects. In vivo, si-DCTPP1 decreased tumor weight and growth. si-DCTPP1 synergistically reduced E-cadherin and TGF-β expression. Conclusion : DCTPP1 stimulates malignant characteristics in breast cancer. Its knockdown enhances docetaxel efficacy, indicating that DCTPP1 is a possible therapeutic biomarker.